nodes	percent_of_prediction	percent_of_DWPC	metapath
Tinidazole—CYP3A4—prostate cancer	0.321	1	CbGaD
Tinidazole—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0938	0.207	CbGbCtD
Tinidazole—CYP3A4—Bicalutamide—prostate cancer	0.0493	0.109	CbGbCtD
Tinidazole—CYP3A4—Estramustine—prostate cancer	0.0458	0.101	CbGbCtD
Tinidazole—CYP3A4—Flutamide—prostate cancer	0.0408	0.09	CbGbCtD
Tinidazole—CYP3A4—Abiraterone—prostate cancer	0.0408	0.09	CbGbCtD
Tinidazole—CYP3A4—Cabazitaxel—prostate cancer	0.0302	0.0666	CbGbCtD
Tinidazole—CYP3A4—Estrone—prostate cancer	0.0295	0.0651	CbGbCtD
Tinidazole—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0263	0.058	CbGbCtD
Tinidazole—CYP3A4—Conjugated Estrogens—prostate cancer	0.0193	0.0426	CbGbCtD
Tinidazole—CYP3A4—Mitoxantrone—prostate cancer	0.0176	0.0387	CbGbCtD
Tinidazole—CYP3A4—Estradiol—prostate cancer	0.017	0.0374	CbGbCtD
Tinidazole—CYP3A4—Prednisone—prostate cancer	0.0146	0.0321	CbGbCtD
Tinidazole—CYP3A4—Etoposide—prostate cancer	0.0111	0.0244	CbGbCtD
Tinidazole—CYP3A4—Docetaxel—prostate cancer	0.0101	0.0223	CbGbCtD
Tinidazole—CYP3A4—Doxorubicin—prostate cancer	0.00755	0.0166	CbGbCtD
Tinidazole—Metronidazole—CYP3A4—prostate cancer	0.00162	1	CrCbGaD
Tinidazole—CYP3A4—Farnesoid X Receptor  Pathway—SULT2A1—prostate cancer	0.000262	0.0101	CbGpPWpGaD
Tinidazole—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—prostate cancer	0.000258	0.00995	CbGpPWpGaD
Tinidazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—prostate cancer	0.00025	0.00963	CbGpPWpGaD
Tinidazole—CYP3A4—Tamoxifen metabolism—SULT2A1—prostate cancer	0.000242	0.00931	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP3A5—prostate cancer	0.000236	0.00908	CbGpPWpGaD
Tinidazole—CYP3A4—Xenobiotics—CYP2C19—prostate cancer	0.000224	0.00862	CbGpPWpGaD
Tinidazole—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—prostate cancer	0.00022	0.00846	CbGpPWpGaD
Tinidazole—CYP3A4—Xenobiotics—CYP2A6—prostate cancer	0.000216	0.00832	CbGpPWpGaD
Tinidazole—CYP3A4—Tamoxifen metabolism—CYP2C19—prostate cancer	0.000216	0.00829	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A43—prostate cancer	0.000214	0.00823	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP3A43—prostate cancer	0.000211	0.00812	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTCD—prostate cancer	0.000209	0.00803	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTK1—prostate cancer	0.000209	0.00803	CbGpPWpGaD
Tinidazole—CYP3A4—Tamoxifen metabolism—CYP2A6—prostate cancer	0.000208	0.008	CbGpPWpGaD
Tinidazole—CYP3A4—Tryptophan metabolism—CYP7B1—prostate cancer	0.000206	0.00791	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—prostate cancer	0.000203	0.00781	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—prostate cancer	0.000201	0.00772	CbGpPWpGaD
Tinidazole—CYP3A4—Estrogen metabolism—NQO1—prostate cancer	0.000198	0.00761	CbGpPWpGaD
Tinidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—prostate cancer	0.000191	0.00735	CbGpPWpGaD
Tinidazole—CYP3A4—Estrogen metabolism—CYP1B1—prostate cancer	0.00019	0.0073	CbGpPWpGaD
Tinidazole—CYP3A4—Xenobiotics—CYP2E1—prostate cancer	0.000184	0.00707	CbGpPWpGaD
Tinidazole—CYP3A4—Tamoxifen metabolism—CYP2E1—prostate cancer	0.000177	0.0068	CbGpPWpGaD
Tinidazole—CYP3A4—Aflatoxin activation and detoxification—GGT1—prostate cancer	0.000176	0.00677	CbGpPWpGaD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A43—prostate cancer	0.000173	0.00667	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.000173	0.00664	CbGpPWpGaD
Tinidazole—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	0.000168	0.00645	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	0.000166	0.0064	CbGpPWpGaD
Tinidazole—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000166	0.00638	CbGpPWpGaD
Tinidazole—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.000165	0.00634	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.000164	0.00631	CbGpPWpGaD
Tinidazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000163	0.00628	CbGpPWpGaD
Tinidazole—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000158	0.00608	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.000154	0.00592	CbGpPWpGaD
Tinidazole—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000152	0.00583	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.000148	0.00571	CbGpPWpGaD
Tinidazole—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	0.000144	0.00553	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	0.000143	0.00549	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	0.000141	0.00542	CbGpPWpGaD
Tinidazole—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	0.000139	0.00535	CbGpPWpGaD
Tinidazole—CYP3A4—Irinotecan Pathway—APC—prostate cancer	0.000138	0.0053	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000135	0.00521	CbGpPWpGaD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	0.000135	0.00519	CbGpPWpGaD
Tinidazole—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000132	0.00508	CbGpPWpGaD
Tinidazole—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	0.000127	0.00489	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	0.000126	0.00485	CbGpPWpGaD
Tinidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.00012	0.00463	CbGpPWpGaD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000116	0.00445	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000114	0.00439	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.000112	0.00432	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000111	0.00427	CbGpPWpGaD
Tinidazole—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000109	0.00418	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	0.000103	0.00397	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	0.000103	0.00397	CbGpPWpGaD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	0.000102	0.00393	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	0.000102	0.00392	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—GSTM3—prostate cancer	9.71e-05	0.00374	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	9.71e-05	0.00374	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	9.58e-05	0.00369	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	9.58e-05	0.00369	CbGpPWpGaD
Tinidazole—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	9.44e-05	0.00363	CbGpPWpGaD
Tinidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	9.37e-05	0.00361	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	9.31e-05	0.00358	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	9.21e-05	0.00354	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—NAT1—prostate cancer	9.21e-05	0.00354	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	9.18e-05	0.00353	CbGpPWpGaD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	9.1e-05	0.0035	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	9.08e-05	0.00349	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	8.98e-05	0.00346	CbGpPWpGaD
Tinidazole—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	8.95e-05	0.00344	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	8.86e-05	0.00341	CbGpPWpGaD
Tinidazole—Arthralgia—Docetaxel—prostate cancer	8.6e-05	0.000435	CcSEcCtD
Tinidazole—Myalgia—Docetaxel—prostate cancer	8.6e-05	0.000435	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	8.6e-05	0.00331	CbGpPWpGaD
Tinidazole—Gastrointestinal disorder—Etoposide—prostate cancer	8.57e-05	0.000433	CcSEcCtD
Tinidazole—Asthenia—Mitoxantrone—prostate cancer	8.56e-05	0.000433	CcSEcCtD
Tinidazole—Fatigue—Etoposide—prostate cancer	8.56e-05	0.000433	CcSEcCtD
Tinidazole—Neuropathy peripheral—Epirubicin—prostate cancer	8.55e-05	0.000432	CcSEcCtD
Tinidazole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.54e-05	0.000432	CcSEcCtD
Tinidazole—Stomatitis—Epirubicin—prostate cancer	8.5e-05	0.00043	CcSEcCtD
Tinidazole—Constipation—Etoposide—prostate cancer	8.49e-05	0.000429	CcSEcCtD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	8.48e-05	0.00327	CbGpPWpGaD
Tinidazole—Urinary tract infection—Epirubicin—prostate cancer	8.48e-05	0.000429	CcSEcCtD
Tinidazole—Dizziness—Estradiol—prostate cancer	8.47e-05	0.000428	CcSEcCtD
Tinidazole—Dysuria—Doxorubicin—prostate cancer	8.46e-05	0.000428	CcSEcCtD
Tinidazole—Neutropenia—Doxorubicin—prostate cancer	8.46e-05	0.000428	CcSEcCtD
Tinidazole—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	8.42e-05	0.00324	CbGpPWpGaD
Tinidazole—Sweating—Epirubicin—prostate cancer	8.36e-05	0.000423	CcSEcCtD
Tinidazole—Myalgia—Capecitabine—prostate cancer	8.33e-05	0.000421	CcSEcCtD
Tinidazole—Arthralgia—Capecitabine—prostate cancer	8.33e-05	0.000421	CcSEcCtD
Tinidazole—Confusional state—Docetaxel—prostate cancer	8.32e-05	0.000421	CcSEcCtD
Tinidazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.27e-05	0.000418	CcSEcCtD
Tinidazole—Discomfort—Capecitabine—prostate cancer	8.23e-05	0.000416	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	8.19e-05	0.00315	CbGpPWpGaD
Tinidazole—Feeling abnormal—Etoposide—prostate cancer	8.18e-05	0.000414	CcSEcCtD
Tinidazole—Diarrhoea—Mitoxantrone—prostate cancer	8.16e-05	0.000413	CcSEcCtD
Tinidazole—Vomiting—Estradiol—prostate cancer	8.14e-05	0.000412	CcSEcCtD
Tinidazole—Gastrointestinal pain—Etoposide—prostate cancer	8.12e-05	0.00041	CcSEcCtD
Tinidazole—Nervous system disorder—Docetaxel—prostate cancer	8.09e-05	0.000409	CcSEcCtD
Tinidazole—Ill-defined disorder—Prednisone—prostate cancer	8.09e-05	0.000409	CcSEcCtD
Tinidazole—Thrombocytopenia—Docetaxel—prostate cancer	8.08e-05	0.000408	CcSEcCtD
Tinidazole—Rash—Estradiol—prostate cancer	8.07e-05	0.000408	CcSEcCtD
Tinidazole—Drowsiness—Doxorubicin—prostate cancer	8.07e-05	0.000408	CcSEcCtD
Tinidazole—Dermatitis—Estradiol—prostate cancer	8.07e-05	0.000408	CcSEcCtD
Tinidazole—Confusional state—Capecitabine—prostate cancer	8.05e-05	0.000407	CcSEcCtD
Tinidazole—Headache—Estradiol—prostate cancer	8.02e-05	0.000406	CcSEcCtD
Tinidazole—Skin disorder—Docetaxel—prostate cancer	8.01e-05	0.000405	CcSEcCtD
Tinidazole—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	8e-05	0.000405	CcSEcCtD
Tinidazole—Angioedema—Prednisone—prostate cancer	7.96e-05	0.000403	CcSEcCtD
Tinidazole—Neuropathy peripheral—Doxorubicin—prostate cancer	7.91e-05	0.0004	CcSEcCtD
Tinidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	7.9e-05	0.00304	CbGpPWpGaD
Tinidazole—Urticaria—Etoposide—prostate cancer	7.88e-05	0.000399	CcSEcCtD
Tinidazole—Stomatitis—Doxorubicin—prostate cancer	7.87e-05	0.000398	CcSEcCtD
Tinidazole—Anorexia—Docetaxel—prostate cancer	7.86e-05	0.000398	CcSEcCtD
Tinidazole—Malaise—Prednisone—prostate cancer	7.86e-05	0.000398	CcSEcCtD
Tinidazole—Body temperature increased—Etoposide—prostate cancer	7.85e-05	0.000397	CcSEcCtD
Tinidazole—Abdominal pain—Etoposide—prostate cancer	7.85e-05	0.000397	CcSEcCtD
Tinidazole—Urinary tract infection—Doxorubicin—prostate cancer	7.84e-05	0.000397	CcSEcCtD
Tinidazole—Nervous system disorder—Capecitabine—prostate cancer	7.83e-05	0.000396	CcSEcCtD
Tinidazole—Vertigo—Prednisone—prostate cancer	7.83e-05	0.000396	CcSEcCtD
Tinidazole—Thrombocytopenia—Capecitabine—prostate cancer	7.82e-05	0.000395	CcSEcCtD
Tinidazole—Hypoaesthesia—Epirubicin—prostate cancer	7.79e-05	0.000394	CcSEcCtD
Tinidazole—Pharyngitis—Epirubicin—prostate cancer	7.77e-05	0.000393	CcSEcCtD
Tinidazole—Skin disorder—Capecitabine—prostate cancer	7.76e-05	0.000392	CcSEcCtD
Tinidazole—Sweating—Doxorubicin—prostate cancer	7.74e-05	0.000391	CcSEcCtD
Tinidazole—Urinary tract disorder—Epirubicin—prostate cancer	7.73e-05	0.000391	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	7.72e-05	0.00297	CbGpPWpGaD
Tinidazole—Hyperhidrosis—Capecitabine—prostate cancer	7.72e-05	0.00039	CcSEcCtD
Tinidazole—Urethral disorder—Epirubicin—prostate cancer	7.68e-05	0.000388	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	7.63e-05	0.00294	CbGpPWpGaD
Tinidazole—Anorexia—Capecitabine—prostate cancer	7.61e-05	0.000385	CcSEcCtD
Tinidazole—Nausea—Estradiol—prostate cancer	7.61e-05	0.000385	CcSEcCtD
Tinidazole—Vomiting—Mitoxantrone—prostate cancer	7.59e-05	0.000384	CcSEcCtD
Tinidazole—Convulsion—Prednisone—prostate cancer	7.55e-05	0.000382	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	7.54e-05	0.0029	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	7.53e-05	0.0029	CbGpPWpGaD
Tinidazole—Rash—Mitoxantrone—prostate cancer	7.52e-05	0.00038	CcSEcCtD
Tinidazole—Dermatitis—Mitoxantrone—prostate cancer	7.52e-05	0.00038	CcSEcCtD
Tinidazole—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.51e-05	0.00038	CcSEcCtD
Tinidazole—Headache—Mitoxantrone—prostate cancer	7.47e-05	0.000378	CcSEcCtD
Tinidazole—Insomnia—Docetaxel—prostate cancer	7.46e-05	0.000377	CcSEcCtD
Tinidazole—Myalgia—Prednisone—prostate cancer	7.42e-05	0.000375	CcSEcCtD
Tinidazole—Arthralgia—Prednisone—prostate cancer	7.42e-05	0.000375	CcSEcCtD
Tinidazole—Paraesthesia—Docetaxel—prostate cancer	7.41e-05	0.000375	CcSEcCtD
Tinidazole—Erythema multiforme—Epirubicin—prostate cancer	7.4e-05	0.000374	CcSEcCtD
Tinidazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.37e-05	0.000373	CcSEcCtD
Tinidazole—Dyspnoea—Docetaxel—prostate cancer	7.35e-05	0.000372	CcSEcCtD
Tinidazole—Somnolence—Docetaxel—prostate cancer	7.33e-05	0.000371	CcSEcCtD
Tinidazole—Discomfort—Prednisone—prostate cancer	7.33e-05	0.000371	CcSEcCtD
Tinidazole—Hypersensitivity—Etoposide—prostate cancer	7.31e-05	0.00037	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	7.28e-05	0.0028	CbGpPWpGaD
Tinidazole—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.28e-05	0.000368	CcSEcCtD
Tinidazole—Flushing—Epirubicin—prostate cancer	7.27e-05	0.000368	CcSEcCtD
Tinidazole—Dyspepsia—Docetaxel—prostate cancer	7.26e-05	0.000367	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	7.24e-05	0.00278	CbGpPWpGaD
Tinidazole—Insomnia—Capecitabine—prostate cancer	7.22e-05	0.000365	CcSEcCtD
Tinidazole—Hypoaesthesia—Doxorubicin—prostate cancer	7.21e-05	0.000365	CcSEcCtD
Tinidazole—Pharyngitis—Doxorubicin—prostate cancer	7.19e-05	0.000364	CcSEcCtD
Tinidazole—Paraesthesia—Capecitabine—prostate cancer	7.17e-05	0.000363	CcSEcCtD
Tinidazole—Decreased appetite—Docetaxel—prostate cancer	7.17e-05	0.000363	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	7.16e-05	0.00276	CbGpPWpGaD
Tinidazole—Urinary tract disorder—Doxorubicin—prostate cancer	7.15e-05	0.000362	CcSEcCtD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	7.14e-05	0.00275	CbGpPWpGaD
Tinidazole—Gastrointestinal disorder—Docetaxel—prostate cancer	7.12e-05	0.00036	CcSEcCtD
Tinidazole—Asthenia—Etoposide—prostate cancer	7.12e-05	0.00036	CcSEcCtD
Tinidazole—Dyspnoea—Capecitabine—prostate cancer	7.12e-05	0.00036	CcSEcCtD
Tinidazole—Fatigue—Docetaxel—prostate cancer	7.11e-05	0.00036	CcSEcCtD
Tinidazole—Angiopathy—Epirubicin—prostate cancer	7.1e-05	0.000359	CcSEcCtD
Tinidazole—Urethral disorder—Doxorubicin—prostate cancer	7.1e-05	0.000359	CcSEcCtD
Tinidazole—Nausea—Mitoxantrone—prostate cancer	7.09e-05	0.000358	CcSEcCtD
Tinidazole—Immune system disorder—Epirubicin—prostate cancer	7.07e-05	0.000358	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	7.06e-05	0.00272	CbGpPWpGaD
Tinidazole—Constipation—Docetaxel—prostate cancer	7.05e-05	0.000357	CcSEcCtD
Tinidazole—Dyspepsia—Capecitabine—prostate cancer	7.03e-05	0.000356	CcSEcCtD
Tinidazole—Pruritus—Etoposide—prostate cancer	7.02e-05	0.000355	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	6.98e-05	0.00268	CbGpPWpGaD
Tinidazole—Nervous system disorder—Prednisone—prostate cancer	6.98e-05	0.000353	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	6.97e-05	0.00268	CbGpPWpGaD
Tinidazole—Decreased appetite—Capecitabine—prostate cancer	6.94e-05	0.000351	CcSEcCtD
Tinidazole—Skin disorder—Prednisone—prostate cancer	6.91e-05	0.000349	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	6.9e-05	0.00266	CbGpPWpGaD
Tinidazole—Gastrointestinal disorder—Capecitabine—prostate cancer	6.89e-05	0.000349	CcSEcCtD
Tinidazole—Fatigue—Capecitabine—prostate cancer	6.88e-05	0.000348	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	6.88e-05	0.00265	CbGpPWpGaD
Tinidazole—Hyperhidrosis—Prednisone—prostate cancer	6.88e-05	0.000348	CcSEcCtD
Tinidazole—Erythema multiforme—Doxorubicin—prostate cancer	6.85e-05	0.000346	CcSEcCtD
Tinidazole—Constipation—Capecitabine—prostate cancer	6.83e-05	0.000345	CcSEcCtD
Tinidazole—Malnutrition—Epirubicin—prostate cancer	6.82e-05	0.000345	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	6.8e-05	0.00262	CbGpPWpGaD
Tinidazole—Feeling abnormal—Docetaxel—prostate cancer	6.8e-05	0.000344	CcSEcCtD
Tinidazole—Diarrhoea—Etoposide—prostate cancer	6.79e-05	0.000343	CcSEcCtD
Tinidazole—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	6.78e-05	0.00261	CbGpPWpGaD
Tinidazole—Anorexia—Prednisone—prostate cancer	6.78e-05	0.000343	CcSEcCtD
Tinidazole—Gastrointestinal pain—Docetaxel—prostate cancer	6.74e-05	0.000341	CcSEcCtD
Tinidazole—Flushing—Doxorubicin—prostate cancer	6.72e-05	0.00034	CcSEcCtD
Tinidazole—Flatulence—Epirubicin—prostate cancer	6.72e-05	0.00034	CcSEcCtD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	6.71e-05	0.00258	CbGpPWpGaD
Tinidazole—Dysgeusia—Epirubicin—prostate cancer	6.67e-05	0.000338	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	6.64e-05	0.00256	CbGpPWpGaD
Tinidazole—Feeling abnormal—Capecitabine—prostate cancer	6.58e-05	0.000333	CcSEcCtD
Tinidazole—Angiopathy—Doxorubicin—prostate cancer	6.57e-05	0.000332	CcSEcCtD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	6.57e-05	0.00253	CbGpPWpGaD
Tinidazole—Dizziness—Etoposide—prostate cancer	6.56e-05	0.000332	CcSEcCtD
Tinidazole—Muscle spasms—Epirubicin—prostate cancer	6.55e-05	0.000331	CcSEcCtD
Tinidazole—Immune system disorder—Doxorubicin—prostate cancer	6.54e-05	0.000331	CcSEcCtD
Tinidazole—Gastrointestinal pain—Capecitabine—prostate cancer	6.53e-05	0.00033	CcSEcCtD
Tinidazole—Body temperature increased—Docetaxel—prostate cancer	6.52e-05	0.00033	CcSEcCtD
Tinidazole—Abdominal pain—Docetaxel—prostate cancer	6.52e-05	0.00033	CcSEcCtD
Tinidazole—Musculoskeletal discomfort—Prednisone—prostate cancer	6.48e-05	0.000328	CcSEcCtD
Tinidazole—Insomnia—Prednisone—prostate cancer	6.43e-05	0.000325	CcSEcCtD
Tinidazole—Paraesthesia—Prednisone—prostate cancer	6.39e-05	0.000323	CcSEcCtD
Tinidazole—Urticaria—Capecitabine—prostate cancer	6.34e-05	0.000321	CcSEcCtD
Tinidazole—Ill-defined disorder—Epirubicin—prostate cancer	6.32e-05	0.00032	CcSEcCtD
Tinidazole—Body temperature increased—Capecitabine—prostate cancer	6.31e-05	0.000319	CcSEcCtD
Tinidazole—Abdominal pain—Capecitabine—prostate cancer	6.31e-05	0.000319	CcSEcCtD
Tinidazole—Vomiting—Etoposide—prostate cancer	6.31e-05	0.000319	CcSEcCtD
Tinidazole—Malnutrition—Doxorubicin—prostate cancer	6.31e-05	0.000319	CcSEcCtD
Tinidazole—Dyspepsia—Prednisone—prostate cancer	6.26e-05	0.000317	CcSEcCtD
Tinidazole—Rash—Etoposide—prostate cancer	6.26e-05	0.000316	CcSEcCtD
Tinidazole—Dermatitis—Etoposide—prostate cancer	6.25e-05	0.000316	CcSEcCtD
Tinidazole—Headache—Etoposide—prostate cancer	6.22e-05	0.000314	CcSEcCtD
Tinidazole—Flatulence—Doxorubicin—prostate cancer	6.21e-05	0.000314	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	6.19e-05	0.00238	CbGpPWpGaD
Tinidazole—Decreased appetite—Prednisone—prostate cancer	6.18e-05	0.000313	CcSEcCtD
Tinidazole—Dysgeusia—Doxorubicin—prostate cancer	6.18e-05	0.000312	CcSEcCtD
Tinidazole—Malaise—Epirubicin—prostate cancer	6.15e-05	0.000311	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	6.14e-05	0.00236	CbGpPWpGaD
Tinidazole—Fatigue—Prednisone—prostate cancer	6.13e-05	0.00031	CcSEcCtD
Tinidazole—Vertigo—Epirubicin—prostate cancer	6.12e-05	0.00031	CcSEcCtD
Tinidazole—Leukopenia—Epirubicin—prostate cancer	6.1e-05	0.000309	CcSEcCtD
Tinidazole—Constipation—Prednisone—prostate cancer	6.08e-05	0.000308	CcSEcCtD
Tinidazole—Hypersensitivity—Docetaxel—prostate cancer	6.08e-05	0.000307	CcSEcCtD
Tinidazole—Muscle spasms—Doxorubicin—prostate cancer	6.06e-05	0.000307	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	6.06e-05	0.00233	CbGpPWpGaD
Tinidazole—Palpitations—Epirubicin—prostate cancer	6.02e-05	0.000305	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GSTA3—prostate cancer	5.93e-05	0.00228	CbGpPWpGaD
Tinidazole—Asthenia—Docetaxel—prostate cancer	5.92e-05	0.000299	CcSEcCtD
Tinidazole—Convulsion—Epirubicin—prostate cancer	5.91e-05	0.000299	CcSEcCtD
Tinidazole—Nausea—Etoposide—prostate cancer	5.89e-05	0.000298	CcSEcCtD
Tinidazole—Hypersensitivity—Capecitabine—prostate cancer	5.88e-05	0.000298	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	5.87e-05	0.00226	CbGpPWpGaD
Tinidazole—Feeling abnormal—Prednisone—prostate cancer	5.86e-05	0.000296	CcSEcCtD
Tinidazole—Ill-defined disorder—Doxorubicin—prostate cancer	5.85e-05	0.000296	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	5.85e-05	0.00225	CbGpPWpGaD
Tinidazole—Pruritus—Docetaxel—prostate cancer	5.84e-05	0.000295	CcSEcCtD
Tinidazole—Gastrointestinal pain—Prednisone—prostate cancer	5.82e-05	0.000294	CcSEcCtD
Tinidazole—Arthralgia—Epirubicin—prostate cancer	5.8e-05	0.000294	CcSEcCtD
Tinidazole—Myalgia—Epirubicin—prostate cancer	5.8e-05	0.000294	CcSEcCtD
Tinidazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.76e-05	0.000291	CcSEcCtD
Tinidazole—Discomfort—Epirubicin—prostate cancer	5.73e-05	0.00029	CcSEcCtD
Tinidazole—Asthenia—Capecitabine—prostate cancer	5.73e-05	0.00029	CcSEcCtD
Tinidazole—Malaise—Doxorubicin—prostate cancer	5.69e-05	0.000288	CcSEcCtD
Tinidazole—Vertigo—Doxorubicin—prostate cancer	5.67e-05	0.000287	CcSEcCtD
Tinidazole—Urticaria—Prednisone—prostate cancer	5.65e-05	0.000286	CcSEcCtD
Tinidazole—Pruritus—Capecitabine—prostate cancer	5.65e-05	0.000286	CcSEcCtD
Tinidazole—Leukopenia—Doxorubicin—prostate cancer	5.65e-05	0.000286	CcSEcCtD
Tinidazole—Diarrhoea—Docetaxel—prostate cancer	5.64e-05	0.000285	CcSEcCtD
Tinidazole—Abdominal pain—Prednisone—prostate cancer	5.62e-05	0.000284	CcSEcCtD
Tinidazole—Body temperature increased—Prednisone—prostate cancer	5.62e-05	0.000284	CcSEcCtD
Tinidazole—Confusional state—Epirubicin—prostate cancer	5.61e-05	0.000284	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.6e-05	0.00215	CbGpPWpGaD
Tinidazole—Palpitations—Doxorubicin—prostate cancer	5.57e-05	0.000282	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.52e-05	0.00212	CbGpPWpGaD
Tinidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.48e-05	0.00211	CbGpPWpGaD
Tinidazole—Convulsion—Doxorubicin—prostate cancer	5.46e-05	0.000276	CcSEcCtD
Tinidazole—Diarrhoea—Capecitabine—prostate cancer	5.46e-05	0.000276	CcSEcCtD
Tinidazole—Nervous system disorder—Epirubicin—prostate cancer	5.46e-05	0.000276	CcSEcCtD
Tinidazole—Dizziness—Docetaxel—prostate cancer	5.45e-05	0.000276	CcSEcCtD
Tinidazole—Thrombocytopenia—Epirubicin—prostate cancer	5.45e-05	0.000275	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.43e-05	0.00209	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.43e-05	0.00209	CbGpPWpGaD
Tinidazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.41e-05	0.00208	CbGpPWpGaD
Tinidazole—Skin disorder—Epirubicin—prostate cancer	5.4e-05	0.000273	CcSEcCtD
Tinidazole—Hyperhidrosis—Epirubicin—prostate cancer	5.38e-05	0.000272	CcSEcCtD
Tinidazole—Arthralgia—Doxorubicin—prostate cancer	5.37e-05	0.000272	CcSEcCtD
Tinidazole—Myalgia—Doxorubicin—prostate cancer	5.37e-05	0.000272	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.35e-05	0.00206	CbGpPWpGaD
Tinidazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.33e-05	0.00027	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.32e-05	0.00205	CbGpPWpGaD
Tinidazole—Discomfort—Doxorubicin—prostate cancer	5.31e-05	0.000268	CcSEcCtD
Tinidazole—Anorexia—Epirubicin—prostate cancer	5.3e-05	0.000268	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.29e-05	0.00203	CbGpPWpGaD
Tinidazole—Dizziness—Capecitabine—prostate cancer	5.28e-05	0.000267	CcSEcCtD
Tinidazole—Vomiting—Docetaxel—prostate cancer	5.24e-05	0.000265	CcSEcCtD
Tinidazole—Hypersensitivity—Prednisone—prostate cancer	5.24e-05	0.000265	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.22e-05	0.00201	CbGpPWpGaD
Tinidazole—Rash—Docetaxel—prostate cancer	5.2e-05	0.000263	CcSEcCtD
Tinidazole—Dermatitis—Docetaxel—prostate cancer	5.2e-05	0.000263	CcSEcCtD
Tinidazole—Confusional state—Doxorubicin—prostate cancer	5.19e-05	0.000263	CcSEcCtD
Tinidazole—Headache—Docetaxel—prostate cancer	5.17e-05	0.000261	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.15e-05	0.00198	CbGpPWpGaD
Tinidazole—Asthenia—Prednisone—prostate cancer	5.1e-05	0.000258	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.1e-05	0.00196	CbGpPWpGaD
Tinidazole—Vomiting—Capecitabine—prostate cancer	5.08e-05	0.000257	CcSEcCtD
Tinidazole—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.07e-05	0.000256	CcSEcCtD
Tinidazole—Nervous system disorder—Doxorubicin—prostate cancer	5.05e-05	0.000255	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.04e-05	0.00194	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.04e-05	0.00194	CbGpPWpGaD
Tinidazole—Thrombocytopenia—Doxorubicin—prostate cancer	5.04e-05	0.000255	CcSEcCtD
Tinidazole—Rash—Capecitabine—prostate cancer	5.03e-05	0.000255	CcSEcCtD
Tinidazole—Pruritus—Prednisone—prostate cancer	5.03e-05	0.000255	CcSEcCtD
Tinidazole—Insomnia—Epirubicin—prostate cancer	5.03e-05	0.000254	CcSEcCtD
Tinidazole—Dermatitis—Capecitabine—prostate cancer	5.03e-05	0.000254	CcSEcCtD
Tinidazole—Headache—Capecitabine—prostate cancer	5e-05	0.000253	CcSEcCtD
Tinidazole—Skin disorder—Doxorubicin—prostate cancer	5e-05	0.000253	CcSEcCtD
Tinidazole—Paraesthesia—Epirubicin—prostate cancer	5e-05	0.000253	CcSEcCtD
Tinidazole—Hyperhidrosis—Doxorubicin—prostate cancer	4.98e-05	0.000252	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	4.97e-05	0.00191	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	4.97e-05	0.00191	CbGpPWpGaD
Tinidazole—Dyspnoea—Epirubicin—prostate cancer	4.96e-05	0.000251	CcSEcCtD
Tinidazole—Somnolence—Epirubicin—prostate cancer	4.95e-05	0.00025	CcSEcCtD
Tinidazole—Anorexia—Doxorubicin—prostate cancer	4.91e-05	0.000248	CcSEcCtD
Tinidazole—Nausea—Docetaxel—prostate cancer	4.9e-05	0.000248	CcSEcCtD
Tinidazole—Dyspepsia—Epirubicin—prostate cancer	4.9e-05	0.000248	CcSEcCtD
Tinidazole—Diarrhoea—Prednisone—prostate cancer	4.87e-05	0.000246	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	4.84e-05	0.00186	CbGpPWpGaD
Tinidazole—Decreased appetite—Epirubicin—prostate cancer	4.84e-05	0.000245	CcSEcCtD
Tinidazole—Gastrointestinal disorder—Epirubicin—prostate cancer	4.8e-05	0.000243	CcSEcCtD
Tinidazole—Fatigue—Epirubicin—prostate cancer	4.8e-05	0.000243	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	4.77e-05	0.00184	CbGpPWpGaD
Tinidazole—Constipation—Epirubicin—prostate cancer	4.76e-05	0.000241	CcSEcCtD
Tinidazole—Nausea—Capecitabine—prostate cancer	4.74e-05	0.00024	CcSEcCtD
Tinidazole—Dizziness—Prednisone—prostate cancer	4.7e-05	0.000238	CcSEcCtD
Tinidazole—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.69e-05	0.000237	CcSEcCtD
Tinidazole—Insomnia—Doxorubicin—prostate cancer	4.66e-05	0.000235	CcSEcCtD
Tinidazole—Paraesthesia—Doxorubicin—prostate cancer	4.62e-05	0.000234	CcSEcCtD
Tinidazole—Dyspnoea—Doxorubicin—prostate cancer	4.59e-05	0.000232	CcSEcCtD
Tinidazole—Feeling abnormal—Epirubicin—prostate cancer	4.58e-05	0.000232	CcSEcCtD
Tinidazole—Somnolence—Doxorubicin—prostate cancer	4.58e-05	0.000231	CcSEcCtD
Tinidazole—Gastrointestinal pain—Epirubicin—prostate cancer	4.55e-05	0.00023	CcSEcCtD
Tinidazole—Dyspepsia—Doxorubicin—prostate cancer	4.53e-05	0.000229	CcSEcCtD
Tinidazole—Vomiting—Prednisone—prostate cancer	4.52e-05	0.000229	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.5e-05	0.00173	CbGpPWpGaD
Tinidazole—Rash—Prednisone—prostate cancer	4.48e-05	0.000227	CcSEcCtD
Tinidazole—Dermatitis—Prednisone—prostate cancer	4.48e-05	0.000227	CcSEcCtD
Tinidazole—Decreased appetite—Doxorubicin—prostate cancer	4.47e-05	0.000226	CcSEcCtD
Tinidazole—Headache—Prednisone—prostate cancer	4.46e-05	0.000225	CcSEcCtD
Tinidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.45e-05	0.00171	CbGpPWpGaD
Tinidazole—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.44e-05	0.000225	CcSEcCtD
Tinidazole—Fatigue—Doxorubicin—prostate cancer	4.44e-05	0.000224	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.43e-05	0.00171	CbGpPWpGaD
Tinidazole—Urticaria—Epirubicin—prostate cancer	4.42e-05	0.000224	CcSEcCtD
Tinidazole—Constipation—Doxorubicin—prostate cancer	4.4e-05	0.000223	CcSEcCtD
Tinidazole—Abdominal pain—Epirubicin—prostate cancer	4.4e-05	0.000222	CcSEcCtD
Tinidazole—Body temperature increased—Epirubicin—prostate cancer	4.4e-05	0.000222	CcSEcCtD
Tinidazole—Feeling abnormal—Doxorubicin—prostate cancer	4.24e-05	0.000215	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.23e-05	0.00163	CbGpPWpGaD
Tinidazole—Nausea—Prednisone—prostate cancer	4.22e-05	0.000214	CcSEcCtD
Tinidazole—Gastrointestinal pain—Doxorubicin—prostate cancer	4.21e-05	0.000213	CcSEcCtD
Tinidazole—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.18e-05	0.00161	CbGpPWpGaD
Tinidazole—Hypersensitivity—Epirubicin—prostate cancer	4.1e-05	0.000207	CcSEcCtD
Tinidazole—Urticaria—Doxorubicin—prostate cancer	4.09e-05	0.000207	CcSEcCtD
Tinidazole—Abdominal pain—Doxorubicin—prostate cancer	4.07e-05	0.000206	CcSEcCtD
Tinidazole—Body temperature increased—Doxorubicin—prostate cancer	4.07e-05	0.000206	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.03e-05	0.00155	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	4.01e-05	0.00154	CbGpPWpGaD
Tinidazole—Asthenia—Epirubicin—prostate cancer	3.99e-05	0.000202	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	3.95e-05	0.00152	CbGpPWpGaD
Tinidazole—Pruritus—Epirubicin—prostate cancer	3.94e-05	0.000199	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.91e-05	0.00151	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.87e-05	0.00149	CbGpPWpGaD
Tinidazole—Diarrhoea—Epirubicin—prostate cancer	3.81e-05	0.000193	CcSEcCtD
Tinidazole—Hypersensitivity—Doxorubicin—prostate cancer	3.79e-05	0.000192	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.71e-05	0.00143	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.7e-05	0.00142	CbGpPWpGaD
Tinidazole—Asthenia—Doxorubicin—prostate cancer	3.69e-05	0.000187	CcSEcCtD
Tinidazole—Dizziness—Epirubicin—prostate cancer	3.68e-05	0.000186	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.65e-05	0.00141	CbGpPWpGaD
Tinidazole—Pruritus—Doxorubicin—prostate cancer	3.64e-05	0.000184	CcSEcCtD
Tinidazole—Vomiting—Epirubicin—prostate cancer	3.54e-05	0.000179	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.53e-05	0.00136	CbGpPWpGaD
Tinidazole—Diarrhoea—Doxorubicin—prostate cancer	3.52e-05	0.000178	CcSEcCtD
Tinidazole—Rash—Epirubicin—prostate cancer	3.51e-05	0.000177	CcSEcCtD
Tinidazole—Dermatitis—Epirubicin—prostate cancer	3.5e-05	0.000177	CcSEcCtD
Tinidazole—Headache—Epirubicin—prostate cancer	3.48e-05	0.000176	CcSEcCtD
Tinidazole—Dizziness—Doxorubicin—prostate cancer	3.4e-05	0.000172	CcSEcCtD
Tinidazole—Nausea—Epirubicin—prostate cancer	3.3e-05	0.000167	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.29e-05	0.00127	CbGpPWpGaD
Tinidazole—Vomiting—Doxorubicin—prostate cancer	3.27e-05	0.000166	CcSEcCtD
Tinidazole—Rash—Doxorubicin—prostate cancer	3.25e-05	0.000164	CcSEcCtD
Tinidazole—Dermatitis—Doxorubicin—prostate cancer	3.24e-05	0.000164	CcSEcCtD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.24e-05	0.00125	CbGpPWpGaD
Tinidazole—Headache—Doxorubicin—prostate cancer	3.22e-05	0.000163	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.12e-05	0.0012	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.07e-05	0.00118	CbGpPWpGaD
Tinidazole—Nausea—Doxorubicin—prostate cancer	3.06e-05	0.000155	CcSEcCtD
Tinidazole—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.02e-05	0.00116	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.97e-05	0.00114	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.93e-05	0.00113	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.89e-05	0.00111	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.83e-05	0.00109	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—COMT—prostate cancer	2.72e-05	0.00105	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.71e-05	0.00104	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.69e-05	0.00103	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.67e-05	0.00103	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.49e-05	0.000959	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.46e-05	0.000946	CbGpPWpGaD
Tinidazole—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.36e-05	0.000909	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HAO1—prostate cancer	2.33e-05	0.000897	CbGpPWpGaD
Tinidazole—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.33e-05	0.000896	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ADI1—prostate cancer	1.9e-05	0.000731	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GRHL1—prostate cancer	1.9e-05	0.000731	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CSAD—prostate cancer	1.9e-05	0.000731	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PSAT1—prostate cancer	1.9e-05	0.000731	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—TST—prostate cancer	1.9e-05	0.000731	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CBR1—prostate cancer	1.9e-05	0.000731	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CKMT2—prostate cancer	1.77e-05	0.00068	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.77e-05	0.00068	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.77e-05	0.00068	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GRHPR—prostate cancer	1.77e-05	0.00068	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—AOX1—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTM3—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—RFK—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PGAM2—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NAGLU—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.66e-05	0.000639	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.57e-05	0.000606	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—AMACR—prostate cancer	1.57e-05	0.000606	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—DEGS1—prostate cancer	1.57e-05	0.000606	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.57e-05	0.000606	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NAT1—prostate cancer	1.57e-05	0.000606	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.5e-05	0.000578	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.34e-05	0.000515	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HPGD—prostate cancer	1.34e-05	0.000515	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.26e-05	0.000484	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.22e-05	0.000471	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—MTAP—prostate cancer	1.22e-05	0.000471	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.19e-05	0.000459	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.19e-05	0.000459	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ACSL4—prostate cancer	1.14e-05	0.000438	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.14e-05	0.000438	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—UMPS—prostate cancer	1.09e-05	0.00042	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PHGDH—prostate cancer	1.09e-05	0.00042	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ARG2—prostate cancer	1.09e-05	0.00042	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—LDHB—prostate cancer	1.07e-05	0.000412	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.05e-05	0.000404	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—UCP3—prostate cancer	1.01e-05	0.00039	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—TCN2—prostate cancer	1.01e-05	0.00039	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PDHA1—prostate cancer	1.01e-05	0.00039	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTA3—prostate cancer	1.01e-05	0.00039	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HSD3B1—prostate cancer	9.68e-06	0.000372	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SLC22A3—prostate cancer	9.68e-06	0.000372	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTA4—prostate cancer	9.28e-06	0.000357	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.28e-06	0.000357	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTA2—prostate cancer	9.04e-06	0.000348	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.93e-06	0.000344	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ABCG5—prostate cancer	8.93e-06	0.000344	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTA1—prostate cancer	8.72e-06	0.000336	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTO1—prostate cancer	8.63e-06	0.000332	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.63e-06	0.000332	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NAT2—prostate cancer	8.63e-06	0.000332	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PLCB2—prostate cancer	8.27e-06	0.000318	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—LRP2—prostate cancer	8.27e-06	0.000318	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.27e-06	0.000318	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—P4HB—prostate cancer	8.11e-06	0.000312	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.89e-06	0.000304	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.69e-06	0.000296	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—MED12—prostate cancer	7.56e-06	0.000291	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GNG5—prostate cancer	7.5e-06	0.000289	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NCOA3—prostate cancer	7.23e-06	0.000278	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—HPGDS—prostate cancer	6.9e-06	0.000265	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.85e-06	0.000264	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTT1—prostate cancer	6.69e-06	0.000257	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ACHE—prostate cancer	6.69e-06	0.000257	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.61e-06	0.000254	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.43e-06	0.000248	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PRKACB—prostate cancer	6.4e-06	0.000246	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.33e-06	0.000244	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NCOA2—prostate cancer	6.03e-06	0.000232	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.76e-06	0.000221	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.62e-06	0.000216	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NQO1—prostate cancer	5.56e-06	0.000214	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—TH—prostate cancer	5.48e-06	0.000211	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.33e-06	0.000205	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GGT1—prostate cancer	5.16e-06	0.000199	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NCOA1—prostate cancer	5.08e-06	0.000196	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.01e-06	0.000193	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—RXRA—prostate cancer	4.84e-06	0.000186	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—COMT—prostate cancer	4.66e-06	0.000179	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTP1—prostate cancer	4.64e-06	0.000178	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ITPR1—prostate cancer	4.56e-06	0.000176	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—TYMS—prostate cancer	4.31e-06	0.000166	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—GSTM1—prostate cancer	4.26e-06	0.000164	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—LPL—prostate cancer	4.18e-06	0.000161	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.04e-06	0.000155	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—ERCC2—prostate cancer	4.01e-06	0.000154	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—MTHFR—prostate cancer	3.77e-06	0.000145	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PPARA—prostate cancer	3.69e-06	0.000142	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CAV1—prostate cancer	3.47e-06	0.000134	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.16e-06	0.000122	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—INS—prostate cancer	2.99e-06	0.000115	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—CREBBP—prostate cancer	2.93e-06	0.000113	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.78e-06	0.000107	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—NOS3—prostate cancer	2.63e-06	0.000101	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.42e-06	9.33e-05	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PTGS2—prostate cancer	2.4e-06	9.24e-05	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PTEN—prostate cancer	2.09e-06	8.06e-05	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—EP300—prostate cancer	2e-06	7.69e-05	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.48e-06	5.69e-05	CbGpPWpGaD
Tinidazole—CYP3A4—Metabolism—AKT1—prostate cancer	1.21e-06	4.65e-05	CbGpPWpGaD
